Industry News
-
Personalized Gene Editing Advances Face Regulatory Challenges
Apr 01 2026 -
Beam Therapeutics Publishes Base Editing Clinical Data for Sickle Cell Disease Therapy
Apr 01 2026 -
Ray Therapeutics’ AAV Optogenetic Gene Therapy RTx-015 Receives FDA RMAT Designation for Retinitis Pigmentosa
Apr 01 2026 -
Ocugen Completes Enrollment and Dosing in Phase 2/3 GARDian3 Trial for AAV Gene Therapy OCU410ST in Stargardt Disease
Apr 01 2026 -
BrainStorm Advances NurOwn ALS Program and Highlights Long-Term Survival Data
Mar 31 2026 -
First Engineered tRNA Therapy AP003 Advances to Phase 1 Clinical Trial in Australia
Mar 31 2026 -
AviadoBio AAV Gene Therapy AVB-101 Advances to Fourth Cohort in Phase 1/2 ASPIRE-FTD Trial
Mar 31 2026 -
FDA Grants Accelerated Approval to Rocket Pharma’s Gene Therapy Kresladi for Rare Immune Disorder LAD-I
Mar 31 2026 -
Lexeo Therapeutics Advances AAV Gene Therapy Pipeline for Cardiovascular Diseases
Mar 30 2026